What is the maximum dose of terbutaline (a beta-2 adrenergic agonist) to be administered to a pregnant woman during an external cephalic version (ECV) procedure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The maximum dose of terbutaline that can be given to a pregnant mother during external cephalic version (ECV) is typically 0.25 mg administered subcutaneously. This single dose is generally considered safe and effective for uterine relaxation during the procedure. Terbutaline is a beta-2 adrenergic agonist that works by relaxing the uterine smooth muscle, which facilitates easier manipulation of the fetus from breech to cephalic presentation. The medication typically takes effect within 5-15 minutes after administration and lasts for approximately 2-4 hours.

Some key points to consider when administering terbutaline for ECV include:

  • Side effects that should be monitored include maternal tachycardia, palpitations, tremors, and rarely pulmonary edema 1, 2.
  • Blood pressure and heart rate should be monitored before and after administration.
  • Terbutaline should be used with caution in mothers with cardiac disease, hypertension, hyperthyroidism, or diabetes.
  • Alternative tocolytics that may be considered include nitroglycerin or nifedipine, though terbutaline remains commonly used due to its effectiveness and relatively good safety profile when administered as a single dose for ECV 3, 4.

It's worth noting that the most recent and highest quality study on this topic is from 2009 3, which compared oral nifedipine versus subcutaneous terbutaline tocolysis for external cephalic version. However, the study that directly answers the question of the maximum dose of terbutaline is from 2004 1 and 1997 2, which both support the use of 0.25 mg of subcutaneous terbutaline for ECV.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.